The European Medicines Agency’s human drugs committee, the CHMP, has recommended EU approval of CSL Behring/uniQure’s Hemgenix (etranacogene dezaparvovec), the first gene therapy for treating patients with hemophilia B.
Hemophilia B Gene Therapy Among Five Drugs On Track For EU-Wide Approval
Alongside CSL/Behring/uniQure’s Hemgenix (etranacogene dezaparvovec), the European Medicines Agency has given the green light to new drugs for liver cancer, NSCLC, Pompe disease and multiple sclerosis. But it turned down omburtamab for treating the rare cancer, neuroblastoma.
